United Therapeutics (UTHR) Downgraded by ValuEngine

United Therapeutics (NASDAQ:UTHR) was downgraded by equities research analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a note issued to investors on Friday.

UTHR has been the topic of several other reports. Zacks Investment Research upgraded shares of United Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 9th. HC Wainwright reiterated a “hold” rating and issued a $95.00 price objective on shares of United Therapeutics in a research report on Thursday, October 26th. Cowen reiterated a “hold” rating and issued a $129.00 price objective on shares of United Therapeutics in a research report on Friday, October 27th. Oppenheimer boosted their price objective on shares of United Therapeutics to $180.00 and gave the stock an “outperform” rating in a research report on Friday, January 5th. Finally, Credit Suisse Group reiterated an “underperform” rating and issued a $118.00 price objective on shares of United Therapeutics in a research report on Thursday, January 18th. Four analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $140.27.

Shares of United Therapeutics (NASDAQ UTHR) opened at $133.31 on Friday. United Therapeutics has a 1 year low of $112.01 and a 1 year high of $169.89. The company has a market cap of $5,760.46, a PE ratio of 11.76 and a beta of 1.26.

In other United Therapeutics news, Director Christopher Causey sold 580 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $134.72, for a total value of $78,137.60. Following the transaction, the director now directly owns 1,555 shares in the company, valued at approximately $209,489.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,241 shares of the company’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $128.95, for a total transaction of $160,026.95. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,976 shares of company stock worth $1,472,788. 7.80% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP increased its stake in shares of United Therapeutics by 537.3% during the 3rd quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 822 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of United Therapeutics during the 3rd quarter valued at about $156,000. SeaCrest Wealth Management LLC acquired a new position in shares of United Therapeutics during the 4th quarter valued at about $178,000. HL Financial Services LLC acquired a new position in shares of United Therapeutics during the 4th quarter valued at about $217,000. Finally, CIBC Asset Management Inc acquired a new position in shares of United Therapeutics during the 4th quarter valued at about $220,000.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/04/united-therapeutics-uthr-downgraded-by-valuengine.html.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply